Video Interview: Hojabr Alimi, Chief Executive Officer, President & Director, Oculus...

Video Interview: Hojabr Alimi, Chief Executive Officer, President & Director,
Oculus Innovative Sciences, Inc.

NEW YORK, April 17, 2008 (PRIME NEWSWIRE) -- Veteran business journalist Sasha
Salama joins Hojabr Alimi, Chief Executive Officer, President & Director, Oculus
Innovative Sciences, Inc. (Nasdaq:OCLS), to discuss the company's industry,
strategy, financials and positioning.

Click here to view video:
http://investor.shareholder.com/ceosignature/webcast.cfm?mediaid=30774&k=AC93775
20A3CBDF638FBFF18896BEAB

Hojabr Alimi, one of our founders, has served as our chief executive officer,
president and director since 1999 and was appointed as chairman of the board of
directors in June 2006. Prior to co-founding our company with his spouse in
1999, Mr. Alimi was a corporate microbiologist for Arterial Vascular
Engineering. Mr. Alimi received a B.A. in biology from Sonoma State University.

About Oculus Innovative Sciences, Inc.:

Oculus Innovative Sciences, Inc. is a biopharmaceutical company focused on the
development, manufacture and marketing of a family of products intended to help
prevent and treat infection in acute and chronic wounds. Oculus' platform
technology, called Microcyn(r), is a non-irritating shelf-stable solution
containing oxychlorine compounds that is designed to treat a wide range of
pathogens, including antibiotic-resistant strains of bacteria (including MRSA),
as well as viruses, fungi and spores.

For more information on the opportunity to have your CEO discuss your company,
please call NASDAQ CEO Signature Series, 978/461-3141.

The NASDAQ CEO Signature Series logo is available at
http://www.primenewswire.com/newsroom/prs/?pkgid=4839